Literature DB >> 6603844

Dual effects of macrolide antibiotics on rat liver cytochrome P-450. Induction and formation of metabolite-complexes: a structure-activity relationship.

M Delaforge, M Jaouen, D Mansuy.   

Abstract

Previous studies have shown that the macrolide antibiotics, troleandomycin and erythromycin, are able to induce their own transformation into a metabolite forming an inactivated complex with rat liver cytochrome P-450. This paper reports the results of a study on the effects of several macrolide antibiotics including oleandomycin, erythromycin derivatives, josamycin, methymycin, tylosin, spiramycin and rifampicin, as well as antibiotics of other series, such as tetracycline and lincomycin, on rat liver cytochromes P-450 in vivo and in vitro. Only the antibiotics containing the desosamine and mycaminose amino sugars were able to give the dual effects already found with troleandomycin: induction of cytochrome p-450 and formation of an inhibitory cytochrome P-450--iron--nitrosoalkane metabolite complex in vivo or in vitro. From these studies, it appears that two structural factors are important for a macrolide antibiotic to lead to such effects: the presence of a non-hindered readily accessible N-dimethylamino group and the hydrophobic character of the molecule. These data are discussed in relation to the adverse effects observed during drug associations involving some of these macrolide antibiotics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603844     DOI: 10.1016/0006-2952(83)90178-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

2.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.

Authors:  Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

Review 3.  Inhibition and induction of cytochrome P450 and the clinical implications.

Authors:  J H Lin; A Y Lu
Journal:  Clin Pharmacokinet       Date:  1998-11       Impact factor: 6.447

4.  Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels.

Authors:  D C Metz; H D Getz
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

5.  Evaluation of Strategies for the Assessment of Drug-Drug Interactions Involving Cytochrome P450 Enzymes.

Authors:  Jelle Reinen; Martijn Smit; Mira Wenker
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

6.  Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions.

Authors:  H Bohets; K Lavrijsen; J Hendrickx; J van Houdt; V van Genechten; P Verboven; W Meuldermans; J Heykants
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

7.  Indomethacin induced hepatic alterations in mono-oxygenase system and faecal Clostridium perfringens enterotoxin in the rat.

Authors:  M E Fracasso; R Leone; L Cuzzolin; P Del Soldato; G P Velo; G Benoni
Journal:  Agents Actions       Date:  1990-11

8.  Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers.

Authors:  T D Lindstrom; B R Hanssen; S A Wrighton
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

Review 9.  Macrolide antibacterials. Drug interactions of clinical significance.

Authors:  N A von Rosensteil; D Adam
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 10.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.